Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.
Zozaya N, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, Delgado Sánchez O, Dolz Sinisterra F, García-Ruiz A, Herranz Pinto P, Manfredi A, Martínez Olmos J, Morales de Los Ríos Luna P, Puig L, Ros S, HIdalgo-Vega Á.
Zozaya N, et al. Among authors: hidalgo vega a.
Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):941-953. doi: 10.1080/14737167.2022.2063842. Epub 2022 Apr 25.
Expert Rev Pharmacoecon Outcomes Res. 2022.
PMID: 35404728
Free article.